Mintz served as legal counsel to DermTech, Inc. (NASDAQ: DMTK; DermTech), a leader in precision dermatology enabled by a non-invasive skin genomics platform, in its $143.7 million underwritten public offering of common stock, which included the full exercise of underwriters’ option to purchase additional shares. The public offering closed on January 11, 2021.
Headquartered in La Jolla, California, DermTech is the leading genomics company in dermatology and is creating a new category of medicine, precision dermatology, enabled by its non-invasive skin genomics platform. The company’s mission is to transform dermatology with its non-invasive skin genomics platform, to democratize access to high quality dermatology care, and to improve the lives of millions. DermTech provides genomic analysis of skin samples collected non-invasively using an adhesive patch rather than a scalpel. The company also markets and develops products that facilitate the early detection of skin cancers, and is developing products that assess inflammatory diseases and customize drug treatments.
DermTech currently intends to use the net proceeds from the offering to fund further commercialization of its clinical commercial tests, accelerate pipeline development and for general corporate purposes, including working capital and other general and administrative purposes.
The Mintz team advising DermTech was led by Member and Co-chair of the Venture Capital & Emerging Companies Practice Jeremy Glaser, and included Member Melanie Ruthrauff Levy and Associates Peter Cunningham and Jason Miller.
Last year, Mintz represented DermTech its $65 million private investment in public equity (PIPE) financing. In 2019, the firm also represented DermTech in connection with its reverse merger with a publicly traded special purpose acquisition company (SPAC).
Mintz is one of the leading law firms to the life sciences industry. The firm’s attorneys advise hundreds of businesses and other organizations across the sector — from start-ups and emerging growth companies to large public companies, as well as venture capital firms, investment banks, and research and academic institutions — on pivotal deals, mission-critical disputes, intellectual property, and regulatory matters.
Learn more about Mintz’s Life Sciences Practice here.
Learn more about the firm's Venture Capital & Emerging Companies Practice here.
Learn more about the firm’s SPAC Practice here.